{"id":"https://openalex.org/W2590583069","doi":"https://doi.org/10.1200/jco.2005.23.16_suppl.3132","title":"A phase I dose escalation trial of pulsatile high dose gefitinib and docetaxel in patients with an advanced solid tumor","display_name":"A phase I dose escalation trial of pulsatile high dose gefitinib and docetaxel in patients with an advanced solid tumor","publication_year":2005,"publication_date":"2005-06-01","ids":{"openalex":"https://openalex.org/W2590583069","doi":"https://doi.org/10.1200/jco.2005.23.16_suppl.3132","mag":"2590583069"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2005.23.16_suppl.3132","doi":"https://doi.org/10.1200/jco.2005.23.16_suppl.3132","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2005.23.16_suppl.3132","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-3","ki-jl-3","medline","norway-2"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5072271778","display_name":"Matthew G. Fury","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M. G. Fury","raw_affiliation_strings":["Memorial Sloan-Kettering Cancer Ctr, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Memorial Sloan-Kettering Cancer Ctr, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039791495","display_name":"Mark G. Kris","orcid":"https://orcid.org/0000-0002-7317-5341","observed_orcids":["https://orcid.org/0000-0002-7317-5341"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M. Kris","raw_affiliation_strings":["Memorial Sloan-Kettering Cancer Ctr, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Memorial Sloan-Kettering Cancer Ctr, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102710156","display_name":"David B. Solit","orcid":"https://orcid.org/0000-0002-6614-802X","observed_orcids":["https://orcid.org/0000-0002-6614-802X"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"D. Solit","raw_affiliation_strings":["Memorial Sloan-Kettering Cancer Ctr, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Memorial Sloan-Kettering Cancer Ctr, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005775817","display_name":"David G. Pfister","orcid":"https://orcid.org/0000-0002-2109-3221","observed_orcids":["https://orcid.org/0000-0002-2109-3221"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"D. G. Pfister","raw_affiliation_strings":["Memorial Sloan-Kettering Cancer Ctr, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Memorial Sloan-Kettering Cancer Ctr, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052336062","display_name":"Christopher G. Azzoli","orcid":"https://orcid.org/0000-0003-0136-7317","observed_orcids":["https://orcid.org/0000-0003-0136-7317"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"C. G. Azzoli","raw_affiliation_strings":["Memorial Sloan-Kettering Cancer Ctr, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Memorial Sloan-Kettering Cancer Ctr, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051299486","display_name":"Roxanne Henry","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"R. Henry","raw_affiliation_strings":["Memorial Sloan-Kettering Cancer Ctr, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Memorial Sloan-Kettering Cancer Ctr, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018114434","display_name":"Y.B. Su","orcid":"https://orcid.org/0000-0001-9829-0525","observed_orcids":["https://orcid.org/0000-0001-9829-0525"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Y. B. Su","raw_affiliation_strings":["Memorial Sloan-Kettering Cancer Ctr, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Memorial Sloan-Kettering Cancer Ctr, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5075877134","display_name":"Naiyer A. Rizvi","orcid":"https://orcid.org/0000-0002-1134-7494","observed_orcids":["https://orcid.org/0000-0002-1134-7494"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"N. Rizvi","raw_affiliation_strings":["Memorial Sloan-Kettering Cancer Ctr, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Memorial Sloan-Kettering Cancer Ctr, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I1334819555"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"23","issue":"16_suppl","first_page":"3132","last_page":"3132"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9765999913215637,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9765999913215637,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.007899999618530273,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.00279999990016222,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/gefitinib","display_name":"gefitinib","score":0.9919999837875366},{"id":"https://openalex.org/keywords/docetaxel","display_name":"docetaxel","score":0.996999979019165},{"id":"https://openalex.org/keywords/egfr-tyrosine-kinase-inhibitors","display_name":"EGFR tyrosine kinase inhibitors","score":0.8669999837875366},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.7409999966621399},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.9470000267028809},{"id":"https://openalex.org/keywords/advanced-solid-tumors","display_name":"advanced solid tumors","score":0.7879999876022339},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.8999999761581421},{"id":"https://openalex.org/keywords/hyperbilirubinemia","display_name":"hyperbilirubinemia","score":0.7820000052452087},{"id":"https://openalex.org/keywords/neutropenia","display_name":"neutropenia","score":0.8790000081062317},{"id":"https://openalex.org/keywords/skin-rash","display_name":"rash","score":0.531000018119812},{"id":"https://openalex.org/keywords/drug-toxicity","display_name":"drug toxicity","score":0.42899999022483826},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.7269999980926514},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.640999972820282},{"id":"https://openalex.org/keywords/anaplastic-thyroid-carcinoma","display_name":"anaplastic thyroid carcinoma","score":0.7540000081062317},{"id":"https://openalex.org/keywords/head-and-neck-cancer","display_name":"head and neck cancer","score":0.5540000200271606},{"id":"https://openalex.org/keywords/nasopharyngeal-carcinoma","display_name":"nasopharyngeal carcinoma","score":0.8579999804496765}],"concepts":[{"id":"https://openalex.org/C2780580887","wikidata":"https://www.wikidata.org/wiki/Q417824","display_name":"Gefitinib","level":4,"score":0.9531811475753784},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9212703108787537},{"id":"https://openalex.org/C2781190966","wikidata":"https://www.wikidata.org/wiki/Q420436","display_name":"Docetaxel","level":3,"score":0.7785910964012146},{"id":"https://openalex.org/C2778570526","wikidata":"https://www.wikidata.org/wiki/Q653197","display_name":"Rash","level":2,"score":0.5968255996704102},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5725869536399841},{"id":"https://openalex.org/C2777511904","wikidata":"https://www.wikidata.org/wiki/Q425227","display_name":"Taxane","level":4,"score":0.5699795484542847},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.5433819890022278},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.5154686570167542},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.5033223032951355},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4997994899749756},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3220673203468323},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.2172108292579651},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.09066617488861084}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2005.23.16_suppl.3132","doi":"https://doi.org/10.1200/jco.2005.23.16_suppl.3132","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2005.23.16_suppl.3132","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-3","ki-jl-3","medline","norway-2"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","score":0.4399999976158142,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2509022872","https://openalex.org/W2513994891","https://openalex.org/W2313432166","https://openalex.org/W4362495421","https://openalex.org/W2114282601","https://openalex.org/W2485409297","https://openalex.org/W2101100140","https://openalex.org/W2030869902","https://openalex.org/W2077868815","https://openalex.org/W1970226410"],"abstract_inverted_index":{"3132":[0],"Background:":[1],"Gefitinib":[2,116],"has":[3],"known":[4],"anti-tumor":[5],"activity":[6],"with":[7,23,73,109,161,165,169,174,272,276],"partial":[8,281],"response,":[9],"durable":[10],"stable":[11],"disease":[12,291],"and":[13,20,45,56,86,93,122,171,223,235,290],"symptom":[14,288],"improvement":[15,289],"in":[16,33,48,71,329],"NSCLC.":[17],"Concurrent":[18],"gefitinib":[19,44,54,79,90,105,303],"other":[21],"EGFR-TKI":[22],"chemotherapy":[24,31,154],"failed":[25],"to":[26,77,82,232,315,321],"demonstrate":[27],"an":[28],"advantage":[29],"over":[30],"alone":[32],"phase":[34,68],"3":[35,163,225,324],"studies.":[36],"We":[37,65,129,317],"have":[38,130],"shown":[39],"that":[40,299],"pulsatile":[41,89,300],"administration":[42],"of":[43,88,104,124,191,194,245],"taxane":[46],"therapy":[47],"mice":[49],"xenograft":[50],"studies":[51],"allowed":[52],"for":[53,186],"dose-escalation":[55],"was":[57,118,230,239],"significantly":[58],"more":[59],"effective":[60],"than":[61],"continuous":[62],"therapy.":[63],"Methods:":[64],"initiated":[66],"a":[67,74,280],"1":[69,92,121,156,167,172,199,203,218,244,270],"study":[70,78],"patients":[72,160,164,234,286],"solid":[75],"tumor":[76],"preceding":[80,304],"docetaxel":[81,96,305],"determine":[83],"the":[84,132,187,215],"MTD":[85],"toxicity":[87],"(days":[91],"2)":[94],"+":[95],"(75":[97],"mg/m2":[98],"day":[99],"3).":[100],"The":[101,227],"starting":[102],"dose":[103,111,126,135,189,201,228,246,302,310,322],"is":[106,306],"1000":[107,192],"mg/day":[108,193],"6":[110,233],"escalation":[112],"levels":[113,136],"planned:":[114],"50%\u219250%\u219233%\u219233%\u219225%.":[115],"PK":[117],"obtained":[119],"Cycles":[120],"2":[123,141,248],"each":[125],"level.":[127],"Results:":[128],"completed":[131],"first":[133],"two":[134],"(n=9":[137],"patients).":[138],"Patient":[139],"characteristics:":[140],"F,":[142],"7":[143],"M;":[144],"KPS":[145],"median":[146,150,155],"80%":[147],"(70\u201390%);":[148],"age":[149],"62":[151],"years;":[152],"prior":[153],"regimen":[157],"(0\u20132);":[158],"4":[159,180],"NSCLC,":[162],"H/N,":[166],"patient":[168,173,219,271],"NPC,":[170],"thyroid":[175,274],"cancer.":[176],"Median":[177],"cycles":[178],"=":[179],"(2\u20137).":[181],"No":[182],"DLTs":[183],"were":[184],"observed":[185],"1st":[188],"level":[190,202,229,247,323],"gefitinib.":[195],"Toxicities":[196,241],"during":[197,242],"cycle":[198,243],"at":[200],"(n=3):":[204],"G1\u20132":[205,252,255],"rash":[206,253,314],"(n=3),":[207,254],"G3":[208,264],"neutropenia":[209,259,262],"(n=1),":[210,260,263,266],"G1":[211,267],"diarrhea":[212,268,312],"(n=1).":[213],"At":[214],"2nd":[216],"level,":[217],"experienced":[220,279],"neutropenic":[221],"fever":[222],"grade":[224],"hyperbilirubinemia.":[226],"expanded":[231],"no":[236],"further":[237],"DLT":[238],"observed.":[240],"(1500":[249],"mg/day)":[250],"(n=6):":[251],"fatigue":[256],"(n=2),":[257],"G2":[258],"G4":[261],"hyperbilirubinemia":[265],"(n=2).":[269],"anaplastic":[273],"carcinoma":[275],"dermal":[277],"metastases":[278],"response.":[282],"2/3":[283],"pretreated":[284],"H/N":[285],"had":[287],"stabilization":[292],"(>7":[293],"cycles).":[294],"Conclusions:":[295],"Preliminary":[296],"results":[297],"suggest":[298],"high":[301],"well":[307],"tolerated":[308],"without":[309],"limiting":[311],"or":[313,336,339],"date.":[316],"are":[318],"currently":[319],"accruing":[320],"(gefitinib":[325],"2250":[326],"mg/day).":[327],"Supported":[328],"part":[330],"by":[331],"AstraZeneca.":[332],"Author":[333],"Disclosure":[334],"Employment":[335],"Leadership":[337],"Consultant":[338],"Advisory":[340],"Role":[341],"Stock":[342],"Ownership":[343],"Honoraria":[344],"Research":[345],"Funding":[346],"Expert":[347],"Testimony":[348],"Other":[349],"Remuneration":[350],"AstraZeneca":[351]},"counts_by_year":[],"updated_date":"2026-09-21T07:43:02.447757","created_date":"2025-10-10T00:00:00"}